gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · OVIDHealthcarePharmaceuticals

Ovid Therapeutics Inc. Common Stock (OVID)

$2.74+14.17%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.74▲ 106.02% in range
Nov 4, 2025Low $1.20 · High $2.96Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ovid Therapeutics closed at $2.74 on Nov 4, up 14.17%, 7.4% below its 52-week closing high. Volume of 3.6M shares was 1.91× its 20-day average (above normal).

Split-adjusted performance: +15.6% over one month, -1.4% over six months, +98.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $733K, down 88.3% from a year earlier, with a net margin of -2047.6%.

Short interest was 18.1M shares at the Oct 15 settlement, down 4.6% from the prior report (10.2% of float, 12.6 days to cover).

Market cap$535.1M195.3M shares
Revenue · quarter$733.0K−88.3% YoY
Diluted EPS$-0.08—
P/E · TTM—P/S 338.0×
Net margin-2,047.6%Gross 100.0%
Dividend yieldNone
52-week range1.20 – 2.96−7.4% from high
Volume3.6M1.91× 20-day avg
Volatility · 60d64.9%Annualised
Short % of float10.2%12.6 days to cover
Net cash$117.2MCash $117.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +11.8%1M +15.6%3M +3.4%6M −1.4%YTD +68.1%1Y +98.6%3Y −21.8%5Y −20.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum71
Revenue growth14
Net margin12
Value (low P/E)—
Size62

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short18.1M−4.6% vs prior
Days to cover12.6Settled Oct 15
% of float10.2%
Short vol. 10d45.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
OVIDOvid Therapeutics$2.74+14.17%−1.4%−88.3%−2047.6%—$535.1M
CLYMClimb Bio$9.33−4.31%−23.6%———$535.9MCompare
PBYIPUMA BIOTECHNOLOGY$10.69+4.60%+43.5%+7.8%14.5%20.7$551.8MCompare
NGNENeurogene$27.58+3.41%−14.7%———$551.9MCompare
CAPRCapricor Therapeutics$8.92+8.25%−74.1%———$518.6MCompare
STTKShattuck Labs$5.15−5.85%−22.9%———$516.9MCompare
FTHFaeth Therapeutics$19.99+1.73%————$516.6MCompare
CBIOCrescent Biopharma$13.82+5.82%−23.5%———$513.4MCompare
CTMXCytomX Therapeutics$2.35+7.80%−43.1%−92.4%−1457.4%—$512.1MCompare

News about Ovid Therapeutics

All news →
Here's Why Ovid Therapeutics Stock Popped Higher TodayThe Motley Fool · Mar 18, 2026▲ PositiveOvid Therapeutics Announces Pricing of $60 Million Private PlacementGlobeNewswire Inc. · Mar 18, 2026▲ Positive

Quick answers

What does Ovid Therapeutics do?
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures.
What is OVID's market cap?
$535.12M, based on the Nov 4 close of $2.74.
Does Ovid Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of OVID is sold short?
18.1M shares, 10.2% of float, as of Oct 15, 2026.
What sector is OVID in?
Healthcare, in the Pharmaceuticals industry.

About Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

HQ: New York, NY23 employeesListed May 5, 2017ovidrx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology